Reimbursed Care Access in French Southern Territories

Currently classified as a strictly controlled substance under France’s national list of stupéfiants with no authorised medical use outside approved clinical research. The arrêté listing substances classées comme stupéfiants explicitly includes psilocybine and psilocine. # Additional government guidance reiterates that substances placed on the French list of stupéfiants are prohibited except under express ANSM authorisation for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (ecstasy) is named on France’s list of controlled substances (arrêté application of the Code de la santé publique). # French public policy and enforcement treat MDMA as a stupéfiant with production, possession and distribution prohibited except under explicit ANSM research authorization. #

Esketamine (SPRAVATO) is an authorised medicinal product in France for specific, treatment‑resistant depressive indications and has been the subject of HAS clinical and reimbursement opinions; HAS has evaluated SPRAVATO and maintained reimbursement conditions when used in combination with an oral antidepressant for adults under certain conditions, and specifies strict administration/surveillance requirements including hospital administration and post‑dose monitoring. # HAS documents and earlier CT (Transparency Committee) opinions detail that reimbursement and use are limited to adults meeting treatment‑resistant depression criteria (e.g., failure of at least two different oral antidepressants in the current episode), require prescription by a psychiatrist, and must occur in settings able to perform immediate post‑administration monitoring and emergency care. # Reimbursement in the French system depends on HAS/CEPS decisions and on the patient’s entitlement to French health insurance; for territories administered under French law (including the French Southern Territories) the legal/administrative framework is the same, but practical reimbursement requires affiliation to the French social security/health insurance system and local provision of authorised administration sites.

Ketamine is a controlled substance in France (inscribed on the list of stupéfiants for stricter prescription and traceability since government arrêtés in 2017) but remains an authorised medicinal product for anaesthesia and other approved indications; its use for psychiatric indications (e.g., treatment‑resistant depression) is typically off‑label and delivered in specialised clinical settings rather than via routine reimbursed outpatient prescriptions. # The French regulatory approach requires ketamine products to be handled under the regulatory controls applicable to stupéfiants (secure prescriptions, traceability) while licensed injectable ketamine preparations remain hospital medicines for anaesthesia; psychiatric use (repeated low‑dose infusion protocols) is practised off‑label in tertiary/hospital settings and is not standardly reimbursed as an approved antidepressant indication by HAS unless covered under specific hospital funding pathways or individual arrangements. # Practical access in French Southern Territories would follow French hospital/ANSM authorisations and local availability of hospital services; reimbursement requires patient entitlement to French health insurance and local hospital billing arrangements.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (N,N‑diméthyltryptamine) appears explicitly on the French arrêté list of prohibited substances. # Use, possession and distribution are prohibited except under express ANSM authorisation for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. France’s national lists and implementing arrêtés include DMT and a wide group of controlled tryptamines and related substances; 5‑MeO‑DMT is treated within the national framework that prohibits such tryptamines except for authorised research. # Government guidance clarifies that listed substances are prohibited outside ANSM‑approved research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. France’s regulatory framework lists many alkaloids and psychoactive substances under the stupéfiants regime and prohibits production, possession and use except under ANSM authorisation for research. (See national drug scheduling and MILDECA guidance.) # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (the active constituent in ayahuasca brews) fall under France’s list of controlled substances and are forbidden except by explicit ANSM research authorisation; possession, transport or use can incur criminal penalties under the Code de la santé publique. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is explicitly named on the national prohibited substances list and is therefore illegal outside authorised scientific/medical protocols. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Phenethylamine derivatives (including various 2C‑series compounds and numerous synthetic psychotropes) are encompassed by France’s controlled‑substances arrêtés and are illegal outside ANSM‑approved research and clinical trials. # #